Imitation is the Sincerest Form of Flattery – Anirban Sen Gupta on Novel Platelet-Like PLGA-PSP Nanoparticles
Anirban Sen Gupta, Wallace R. Persons Professor of Engineering in the Department of Biomedical Engineering at Case Western Reserve University, shared a post on LinkedIn:
“People say that imitation is the sincerest form of flattery (I hope it is!).
In any case, today I stumbled upon a paper that was apparently published recently (in September 2025) in International Journal Of Nanomedicine by a team from China where they took the exact same peptides that we had identified and used in our original SynthoPlate design back in 2010, but they put it on PLGA nanoparticles (instead of our liposomal platform) and called it “Novel Platelet-like PLGA-PSP”.
At least they got really great hemostatic outcome in their thrombocytopenic mouse trauma models, corroborating that our original choice of platelet function-mimicking peptides was a good one, and it is adaptable on other particle and polymer platforms!
What do you think, Matthew D. Neal, Michael Bruckman, Christa L. Pawlowski, Tim Pelura?
This is the publication.”
More posts featuring Anirban Sen Gupta on Hemostasis Today.
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease
-
Feb 23, 2026, 15:52Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1